CTOs on the Move

OrthoFX

www.orthofx.com

 
OrthoFX have the best materials technology in the industry, due in large part to Loc Phan, the key scientist behind developing the first ever clear aligner. We are committed to continued polymer technology innovation by hiring a team of industry experts like Loc to understand your needs and pain points, and we can`t do it without your partnership.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.orthofx.com
  • 48890 Milmont Dr 101D
    Fremont, CA USA 94538
  • Phone: 415.936.0006

Executives

Name Title Contact Details

Funding

OrthoFX raised $13M on 07/22/2020

Similar Companies

Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony™ Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony™ Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

SKT

SKT is a Ashland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bach Mobilities Inc

Bach Mobilities Inc is a Escanaba, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

New Directions Behavioral Health

New Directions Behavioral Health, founded in 1995, is dedicated to helping people find a healthy balance and improve health through positive change. We offer managed behavioral healthcare, employee assistance programs, organizational consulting, and health coaching programs. As behavior change experts, we provide a full range of proven practices to help individuals attain healthier and more balanced lifestyles. In fact, we serve the behavioral health needs of millions of people across the nation. New Directions is one of the fastest growing behavioral health care companies in the nation. Our services have earned national recognition and awards for innovation and best practices. And we are accredited by NCQA as an MBHO and by URAC for health utilization management and case management.